Since Cronos Group Inc. (NASDAQ:CRON) and Editas Medicine Inc. (NASDAQ:EDIT) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation of both companies.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group Inc.	N/A	0.00	N/A	-0.03	0.00
Editas Medicine Inc.	31.94M	35.08	109.95M	-2.67	0.00

Table 1 highlights Cronos Group Inc. and Editas Medicine Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 demonstrates the return on assets, net margins and return on equity of Cronos Group Inc. and Editas Medicine Inc.

	Net Margins	Return on Equity	Return on Assets
Cronos Group Inc.	0.00%	0%	0%
Editas Medicine Inc.	-344.24%	-58.1%	-34%

Analyst Recommendations

The following table delivered below contains the ratings and recommendations for Cronos Group Inc. and Editas Medicine Inc.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Cronos Group Inc.	0	1	0	2.00
Editas Medicine Inc.	0	0	0	0.00

Cronos Group Inc. has a 31.58% upside potential and an average price target of $24.

Institutional & Insider Ownership

The shares of both Cronos Group Inc. and Editas Medicine Inc. are owned by institutional investors at 17.34% and 78.7% respectively. 5.15% are Cronos Group Inc.’s share owned by insiders. Competitively, Editas Medicine Inc. has 2.5% of it’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Cronos Group Inc.	5.98%	9.04%	146.67%	68.45%	121.47%	106.54%
Editas Medicine Inc.	13.81%	9.62%	-18.9%	-24.93%	-32.52%	4.7%

For the past year Cronos Group Inc.’s stock price has bigger growth than Editas Medicine Inc.

Summary

Cronos Group Inc. beats Editas Medicine Inc. on 7 of the 10 factors.

Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations (?MMPR?). The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in in Toronto, Canada.

Editas Medicine, Inc. operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. It is developing a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments. Editas Medicine, Inc. has a collaboration and license agreement with Juno Therapeutics, Inc. for the research and development of engineered T cells with chimeric antigen receptors and T cell receptors; and collaboration, option, and license agreement with Adverum Biotechnologies, Inc. to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.